Incidence of Acute Kidney Injury among Patients Treated with Piperacillin-Tazobactam or Meropenem in Combination with Vancomycin by Rutter, Wilbur Cliff & Burgess, David S.
University of Kentucky
UKnowledge
Pharmacy Practice and Science Faculty Publications Pharmacy Practice and Science
7-2018
Incidence of Acute Kidney Injury among Patients
Treated with Piperacillin-Tazobactam or
Meropenem in Combination with Vancomycin
Wilbur Cliff Rutter
University of Kentucky, cliff.rutter@uky.edu
David S. Burgess
University of Kentucky, david.burgess@uky.edu
Right click to open a feedback form in a new tab to let us know how this document benefits you.
Follow this and additional works at: https://uknowledge.uky.edu/pps_facpub
Part of the Microbiology Commons, Pharmacy and Pharmaceutical Sciences Commons, and the
Therapeutics Commons
This Article is brought to you for free and open access by the Pharmacy Practice and Science at UKnowledge. It has been accepted for inclusion in
Pharmacy Practice and Science Faculty Publications by an authorized administrator of UKnowledge. For more information, please contact
UKnowledge@lsv.uky.edu.
Repository Citation
Rutter, Wilbur Cliff and Burgess, David S., "Incidence of Acute Kidney Injury among Patients Treated with Piperacillin-Tazobactam or
Meropenem in Combination with Vancomycin" (2018). Pharmacy Practice and Science Faculty Publications. 36.
https://uknowledge.uky.edu/pps_facpub/36
Incidence of Acute Kidney Injury among Patients Treated with Piperacillin-Tazobactam or Meropenem in
Combination with Vancomycin
Notes/Citation Information
Published in Antimicrobial Agents and Chemotherapy, v. 62, issue 7, e00264-18, p. 1-6.
Copyright © 2018 American Society for Microbiology. All Rights Reserved.
The copyright holder has granted the permission for posting the article here.
Digital Object Identifier (DOI)
https://doi.org/10.1128/AAC.00264-18
This article is available at UKnowledge: https://uknowledge.uky.edu/pps_facpub/36
Incidence of Acute Kidney Injury among Patients Treated with
Piperacillin-Tazobactam or Meropenem in Combination with
Vancomycin
W. Cliff Rutter,a,b David S. Burgessa
aUniversity of Kentucky College of Pharmacy, Lexington, Kentucky, USA
bUniversity of Kentucky HealthCare, Lexington, Kentucky, USA
ABSTRACT Acute kidney injury (AKI) increases during empirical antimicrobial
therapy with the combination of piperacillin-tazobactam (TZP) and vancomycin
(VAN) compared to the number of incidences with monotherapy or the combina-
tion of cefepime and VAN. Limited data regarding the impact of meropenem
(MEM) combined with VAN exist. This study examined the AKI incidence among
patients treated with MEM plus VAN (MEMVAN) or TZPVAN. Data were col-
lected from the University of Kentucky Center for Clinical and Translational Sci-
ence Enterprise Data Trust from September 2007 through October 2015. Adults
without previous renal disease who received MEMVAN or TZPVAN for at least
2 days were included. AKI was assessed using risk, injury, failure, loss, and end-
stage (RIFLE) criteria. Inverse probability of treatment weighting was utilized to
control for differences between groups. In total, 10,236 patients met inclusion
criteria, with 9,898 receiving TZPVAN and 338 receiving MEMVAN. AKI oc-
curred in 15.4% of MEMVAN patients and in 27.4% of TZPVAN patients (P 
0.001). TZPVAN was associated with increased AKI compared to the level with
MEMVAN (odds ratio [OR], 2.53; 95% confidence interval [CI], 1.82 to 3.52), af-
ter controlling for confounders. Use of MEMVAN should be considered an ap-
propriate alternative therapy to TZPVAN if nephrotoxicity is a major concern.
The results of this study demonstrate that judicial use of TZPVAN for empirical
coverage of infection is needed.
KEYWORDS acute kidney injury, combination therapy, vancomycin, beta-lactams
Empirical combination antimicrobial therapy is critical for the treatment of infectionsand sepsis (1, 2). Piperacillin-tazobactam (TZP) is a beta-lactam/beta-lactamase
inhibitor combination that is frequently used concomitantly with vancomycin (VAN;
TZPVAN) for empirical coverage of infections. This combination provides coverage of
clinically important Gram-negative and Gram-positive organisms. While generally con-
sidered safe, recent literature suggests a significant increase in the incidence of
nephrotoxicity with the TZPVAN combination compared to the level with either
agent as monotherapy or to other empirical combinations (3–8). However, this phe-
nomenon has not been noted in all studies (9, 10).
While studies have demonstrated that TZPVAN has significantly increased acute
kidney injury (AKI) incidence compared to that with cefepime and VAN (4, 8, 11), only
one study to date has attempted to compare the use of TZPVAN to that of mero-
penem (MEM) plus VAN (12). In that study, Al Yami was unable to find a significant
difference in AKI incidence among patients receiving TZPVAN compared to that
among patients using MEMVAN. However, this result is limited by small sample size
and lower than anticipated overall AKI incidence.
The current study was designed to determine if a difference in AKI incidence exists
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between TZP or MEM in combination with VAN, with the hypothesis that TZPVAN
would exhibit increased AKI incidence compared to that with MEMVAN.
RESULTS
In total, 10,236 patients met all inclusion criteria, with 338 receiving MEMVAN and
9,898 receiving TZPVAN. Mean age was 53.7 (16.4) years of age, and 58.8% of
patients were male (Table 1). At baseline the MEMVAN cohort tended to be more ill
than patients in the TZPVAN cohort (Charlson comorbidity index [CCI] of 4 [inter-
quartile range, 2 to 6] versus 3 [interquartile range, 1 to 7], respectively; P  0.014) and
more MEMVAN patients had baseline creatinine clearance (CrCl) of 90 ml/min
(58.5% versus 50.6% for TZPVAN; P  0.011). Significantly more patients in the
MEMVAN group had diabetes mellitus (34.0% versus 28.0% for the TZPVAN group,
P 0.018) and hypotension (60.9% versus 51.8% for TZPVAN, P 0.001), with a trend
toward significance in heart failure. The MEMVAN cohort was more likely to be
exposed to concomitant aminoglycosides (3.5% versus 1.5% for the TZPVAN cohort;
TABLE 1 Patient characteristics in treatment groups
Variablea
Value for the group
P valueMEMVAN (n  338) TZPVAN (n  9,898)
Mean age (yr [SD]) 52.3 (16.7) 53.8 (16.4) 0.122
Gender (no. of patients [%]) 0.003
Male 172 (50.9) 5,847 (59.1)
Female 166 (49.1) 4,051 (40.9)
No. (%) of Caucasian patients 317 (93.8) 8,884 (89.8) 0.020
Mean weight (kg [SD]) 84.1 (24.7) 83.3 (24.5) 0.591
BMI (mean [SD]) 29 (8.3) 28.6 (17.0) 0.431
Charlson comorbidity index
(median [IQR])
4 (2–6) 3 (1–7) 0.014
Median baseline CrCl (ml/min
[IQR])
98.3 (69.7–132.5) 90.6 (65.5–120.4) 0.002
Baseline CrCl by group (no.
of patients [%])
0.011
30–59 ml/min 61 (18.0) 1,954 (19.7)
60–89 ml/min 79 (23.4) 2,939 (29.7)
90 ml/min 198 (58.5) 5,005 (50.6)
No. of days of therapy
(median [IQR])
5 (3–8.75) 5 (3–8) 0.891
Comorbidities (no. of
patients [%])
Diabetes mellitus 115 (34.0) 2,771 (28.0) 0.018
Heart failure 64 (18.9) 1,485 (15.0) 0.057
Hypertension 192 (56.8) 5,338 (53.9) 0.324
Hypotension 206 (60.9) 5,131 (51.8) 0.001
Concomitant nephrotoxin
treatment (no. of
patients [%])
Aminoglycoside 60 (17.7) 1,625 (16.4) 0.565
Amphotericin B 12 (3.5) 151 (1.5) 0.007
ACE inhibitor 63 (18.6) 1,966 (19.9) 0.627
ARB 9 (2.7) 294 (3.0) 0.869
Contrast dye 38 (11.2) 484 (4.9) 0.001
Loop diuretic 105 (31.1) 3,603 (36.4) 0.051
NSAID 43 (12.7) 1,515 (15.3) 0.221
Calcineurin inhibitor 22 (6.5) 364 (3.7) 0.011
Vasopressor 55 (16.3) 1,117 (11.3) 0.006
aACE, angiotensin-converting enzyme; ARB, angiotensin II receptor antagonist; CrCl, creatinine clearance; IQR,
interquartile range; MEM, meropenem; NSAID, nonsteroidal anti-inflammatory drugs; SD, standard deviation;
TZP, piperacillin-tazobactam; VAN, vancomycin.
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P 0.007), calcineurin inhibitors (6.5% versus 3.7%; P 0.011), and vasopressors (16.3%
versus 11.3%; P  0.006).
RIFLE-defined AKI occurred in 2,765 (27.0%) patients overall, with AKI being more
common in the TZPVAN group (27.4% versus 15.4%, P  0.0001) (Table 2). Risk and
injury stratifications were significantly more common among the TZPVAN cohort
(15.3% versus 9.8% for MEMVAN [P 0.006], and 7.8% for versus 3.5% for MEMVAN
[P  0.005], respectively) (Fig. 1). There was no significant difference in failure stratifi-
cation (4.2% for TZPVAN versus 2.1% for MEMVAN, P  0.068). A sensitivity analysis
was conducted with AKI being defined as an absolute change in serum creatinine of 0.3
mg/dl from baseline level. AKI was significantly more common in TZPVAN patients in
this analysis (25.9% versus 11.8% for MEMVAN patients, P  0.0001). These findings
suggest that our results are robust to changes in AKI definition.
In inverse probability-weighted logistic regression, TZPVAN treatment was asso-
ciated with a significant increase in AKI odds compared with treatment with MEMVAN
(odds ratio, 2.53; 95% confidence interval, 1.82 to 3.52).
Secondary endpoints did not differ between treatment groups, with 10.3% and
TABLE 2 Primary and secondary outcomes
Outcome by type
Value for the groupc
P value
MEMVAN
(n  338)
TZPVAN
(n  9,898)
Primary outcomes (no. of patients [%])
AKI 52 (15.4) 2,713 (27.4) 0.001
Risk 33 (9.8) 1,516 (15.3) 0.006
Injury 12 (3.5) 777 (7.8) 0.005
Failure 7 (2.1) 420 (4.2) 0.068
Secondary outcomes
Inpatient mortality (no. of patients [%]) 35 (10.3) 1,144 (11.6) 0.552
No. of days of hospitalization (median [IQR])a 9 (6–15) 10 (5–18) 0.482
AKI recovery (no. of patients [%])b 31 (59.6) 1276 (47.0) 0.097
aIQR, interquartile range.
bPercentages represent patients with AKI in the treatment group.
cMEM, meropenem; TZP, piperacillin-tazobactam; VAN, vancomycin.
FIG 1 Acute kidney injury incidence stratified by RIFLE criteria. N, number; MEM, meropenem; TZP,
piperacillin-tazobactam; VAN, vancomycin.
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11.6% of patients in the MEMVAN and TZPVAN groups experiencing mortality (P 
0.552), respectively. Median length of stay was similar between cohorts (MEMVAN
cohort, 9 days [range, 6 to 15 days]; TZPVAN cohort, 10 days [range, 5 to 18 days]
days; P  0.482).
DISCUSSION
In this large retrospective study of AKI among patients receiving meropenem or
piperacillin-tazobactam in combination with vancomycin, we found that combination
therapy with piperacillin-tazobactam is associated with significant increases in AKI
incidence compared to levels with meropenem combination therapy. To our knowl-
edge, this is the largest study to examine this comparison.
Previous investigations of AKI related to TZPVAN therapy have shown incidence
ranges from 9.5% to 34.8% (4, 13). Our findings are consistent with this estimate, with
27.4% of TZPVAN patients experiencing an AKI during therapy. The rate of MEMVAN
treatment-related AKI in the present study differs significantly from that in the study by
Al Yami (15.4% in the present study versus 5.33% in the Al Yami study) (12). This may
be due to differences in patient populations or AKI definitions. In the sensitivity analysis
utilizing a definition of AKI similar to that of Al Yami, 11.8% of patients treated with
MEMVAN experienced AKI. It is important to note that our study included a hetero-
geneous population of critically ill and general medicine patients, similar to the
population in the Al Yami study. Additionally, patients in the TZPVAN cohort in the
Al Yami study had lower AKI incidence than reported in previous literature (7.41%).
Overall differences in AKI between the two studies are likely due to differences in
severity of illness. While Al Yami does not provide a severity-of-illness measure, severe
comorbidities were more prevalent in our study. For example, only 6% of patients in the
Al Yami study had underlying heart failure while the rate was 15.1% in the current
evaluation. Our study differs by having a larger patient sample (10,236 versus 183
patients) than the previous study on this topic, ensuring statistical power to detect a
difference in AKI incidence and to control for confounding.
Antimicrobial resistance is a global health concern, and the overuse of carbapenem
agents can lead to increased carbapenem-resistant organisms being isolated from
patients (14). While significant increases in AKI were noted in TZPVAN-treated pa-
tients, the risk of AKI might be outweighed by resistance development. Cefepime has
been compared to TZP and has consistently been shown to be less nephrotoxic when
used in combination with VAN (4, 8, 11, 15). Head-to-head comparisons of AKI rates
with meropenem and cefepime have not been conducted. In choosing combination
regimens, other clinical factors should be weighed when a patient’s risk for nephro-
toxicity is minimal.
To our knowledge, no human or animal studies have been conducted investigating
the mechanism for this observed increase in AKI with TZPVAN. One hypothesis is that
the addition of a beta-lactamase inhibitor to the beta-lactam/vancomycin combination
may result in increased AKI. However, in a study comparing TZP to ampicillin-sulbactam, no
difference in the incidence of AKI was noted between monotherapy agents (6). The
addition of VAN to TZP or ampicillin-sulbactam resulted in increased AKI incidence
compared to results with either monotherapy, but the magnitude of the increase was
dissimilar between agents. This suggests that the addition of a beta-lactamase inhibitor
is not the factor associated with increased AKI incidence. Gomes and colleagues
suggest that subclinical interstitial nephritis caused by TZP in combination with oxida-
tive stress of VAN may lead to increased renal injury (4). Burgess and Drew posited that
TZP may reduce VAN clearance, resulting in increased exposure in the kidney and thus
in further injury (5). Neither of these mechanisms has been investigated further.
The current study has several limitations. This was a retrospective study, which limits
the causal relationship between drug exposure and outcome; however, we established
a temporal link between the incidence of AKI and administration of the medications
being studied. Additionally, to mimic randomization and limit the impact of confound-
ers, we performed inverse probability weighting to create a balanced pseudopopula-
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tion on which the regression analysis was performed. Sensitivity analyses suggest that
the inverse probability scores were adequate. Nephrotoxin exposures were assessed as
binary variables, a method which does not account for any dosing frequency or
intensity. This may change the estimate of the confounding variables; however, sensi-
tivity analyses using the number of days of nephrotoxin therapy suggests that the
binary treatment is acceptable. Further work to identify optimal handling of concom-
itant nephrotoxins is needed. Duration of beta-lactam infusion was not assessed in this
study; however, previous studies demonstrate that AKI incidence is not associated with
duration of infusion (13, 16, 17). Despite the rigorous study design, there is a possibility
of uncontrolled confounding as unknown confounders may remain. In conclusion, we
found a significant increase in the incidence of AKI with TZPVAN treatment compared
to that with MEMVAN treatment. This finding further underscores the need for judicial
use of TZPVAN as an empirical antimicrobial therapy. Meropenem may be an accept-
able alternative to piperacillin-tazobactam when nephrotoxicity is a major concern.
Further studies of alternative combination therapies are needed to determine what
alternatives have the best safety profile.
MATERIALS AND METHODS
This was an institutional review board (IRB)-approved, retrospective cohort study of adult patients
admitted to the University of Kentucky Medical Center (UKMC) between September 2007 and October
2015. Patients were included if they received MEM or TZP in combination with VAN for at least 2 days.
Patients were excluded for ICD-9 (where ICD is International Classification of Diseases) codes, indicating
a past medical history of chronic kidney disease or cystic fibrosis, baseline creatinine clearance less than
30 ml/min, current procedural codes (CPT) indicating hemodialysis, and pregnancy or breastfeeding.
Data were obtained from the University of Kentucky Center for Clinical and Translational Science
Enterprise Data Trust (EDT). The EDT is an electronic repository of clinical data collected at UKMC and
contains a copy of the digital health record. The EDT is updated nightly and contains demographics,
financial classification, provider-level detail, medical diagnosis, medical procedures, lab tests and results,
medication administration details, visit details, and vital signs. Data collected included patient demo-
graphics and visit information, antimicrobial drug administration data, concomitant nephrotoxin admin-
istration, laboratory results, and baseline comorbidity information.
The primary outcome of this study was the incidence of AKI as defined by the glomerular filtration
rate (GFR) criteria of risk, injury, failure, loss, and end-stage (RIFLE) (18). Only the risk, injury, and failure
stratifications of RIFLE were assessed due to limited follow-up data. GFR was estimated with the adjusted
Cockcroft-Gault equation (19) at baseline and throughout each patient’s hospitalization. AKI that
occurred before treatment, within 48 h treatment initiation, or after 7 days after treatment discontinu-
ation were excluded. Secondary outcomes included length of hospitalization and inpatient mortality,
defined as mortality on date of discharge or transfer to hospice. Additionally, recovery of baseline renal
function was assessed in patients who experienced AKI. Recovery was defined as a return to baseline
renal function or improvement in renal function from baseline at the last collected serum creatinine level.
Severity of baseline comorbidity was assessed with the Charlson comorbidity index (CCI) (20).
Hypotension was defined as mean arterial pressure of 65 mmHg or exposure to vasopressors.
Concomitant nephrotoxin exposure was assessed as receiving at least one dose of the agent within 24
h of initiation of TZP or MEM through the duration of therapy. Concomitant nephrotoxins analyzed
included aminoglycosides, amphotericin B, angiotensin-converting enzyme inhibitors, angiotensin II
receptor antagonists, intravenous radiocontrast dye, loop diuretics, nonsteroidal anti-inflammatory
drugs, calcineurin inhibitors, and vasopressors.
Basic descriptive statistics were performed. Continuous variables were assessed with a Student t test
or Wilcoxon test as appropriate. Categorical variables were assessed with a chi-square or Fisher’s exact
test. Following bivariable analysis, variables that significantly differed between groups and known
confounders regardless of statistical differences were included in an inverse probability of treatment
model to generate weights for the final logistic regression model of AKI odds (21). Statistical significance
was defined as an alpha of 0.05. All data analysis and statistical procedures were conducted with R,
version 3.3.2 (Vienna, Austria), and RStudio, version 0.99.903 (Boston, MA) (22, 23).
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